Adaptimmune Therapeutics (NASDAQ:ADAP) Earns Buy Rating from Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) in a research report issued on Tuesday. The firm set a "buy" rating on the biotechnology company's stock.

Other research analysts have also issued research reports about the company. Jones Trading lowered Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, April 11th. Guggenheim cut their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating for the company in a report on Wednesday, March 26th. HC Wainwright reduced their price objective on shares of Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Wells Fargo & Company lowered their target price on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating on the stock in a research report on Friday, March 21st. Finally, Scotiabank reduced their price target on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating for the company in a research report on Friday, March 21st. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $1.83.

Adaptimmune Therapeutics Stock Performance

ADAP traded down $0.00 during trading on Tuesday, hitting $0.27. The stock had a trading volume of 469,528 shares, compared to its average volume of 1,766,401. The firm has a market capitalization of $68.24 million, a P/E ratio of -1.21 and a beta of 2.84. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. Adaptimmune Therapeutics has a twelve month low of $0.20 and a twelve month high of $1.48. The company's 50-day moving average price is $0.36 and its 200 day moving average price is $0.56.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last posted its quarterly earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. The firm had revenue of $3.22 million for the quarter, compared to analysts' expectations of $16.56 million. On average, equities research analysts forecast that Adaptimmune Therapeutics will post -0.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Jane Street Group LLC increased its position in Adaptimmune Therapeutics by 130.4% during the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company's stock worth $166,000 after buying an additional 98,581 shares in the last quarter. Long Focus Capital Management LLC increased its position in Adaptimmune Therapeutics by 54.1% during the 4th quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company's stock worth $11,040,000 after purchasing an additional 7,194,503 shares in the last quarter. Virtu Financial LLC raised its stake in Adaptimmune Therapeutics by 27.5% in the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company's stock valued at $96,000 after purchasing an additional 21,769 shares during the last quarter. Two Seas Capital LP purchased a new position in Adaptimmune Therapeutics in the 4th quarter valued at about $7,992,000. Finally, Rock Springs Capital Management LP boosted its stake in shares of Adaptimmune Therapeutics by 2.4% during the 4th quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock worth $1,338,000 after purchasing an additional 58,000 shares during the last quarter. 31.37% of the stock is currently owned by institutional investors and hedge funds.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.